Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
$4.04
-3.1%
$3.79
$2.60
$7.77
$236.73M1.56178,862 shs65,012 shs
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
$5.36
+0.3%
$4.33
$2.76
$6.00
$251.69M0.4115,481 shs3,768 shs
Neos Therapeutics, Inc. stock logo
NEOS
Neos Therapeutics
$1.15
$1.06
$0.45
$1.68
$57.22M1.57.44 million shs15.01 million shs
Omeros Corporation stock logo
OMER
Omeros
$3.46
+2.4%
$3.73
$2.95
$13.60
$198.04M2.16735,007 shs784,232 shs
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
-3.12%+7.16%+0.75%+39.79%+11.60%
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
+0.28%+6.89%+11.45%+60.81%-0.76%
Neos Therapeutics, Inc. stock logo
NEOS
Neos Therapeutics
0.00%0.00%0.00%0.00%0.00%
Omeros Corporation stock logo
OMER
Omeros
+2.37%+8.09%-10.82%-48.59%-14.57%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
0.4001 of 5 stars
1.01.00.00.00.62.50.6
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
2.2741 of 5 stars
3.33.00.00.02.90.00.6
Neos Therapeutics, Inc. stock logo
NEOS
Neos Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Omeros Corporation stock logo
OMER
Omeros
3.3055 of 5 stars
3.40.00.04.40.01.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
2.00
Hold$4.00-0.99% Downside
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
2.50
Moderate Buy$8.0049.39% Upside
Neos Therapeutics, Inc. stock logo
NEOS
Neos Therapeutics
0.00
N/AN/AN/A
Omeros Corporation stock logo
OMER
Omeros
2.83
Moderate Buy$18.00420.23% Upside

Current Analyst Ratings Breakdown

Latest NEOS, DSGN, OMER, and NBTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/30/2025
Omeros Corporation stock logo
OMER
Omeros
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$36.00
6/27/2025
Omeros Corporation stock logo
OMER
Omeros
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00
6/10/2025
Omeros Corporation stock logo
OMER
Omeros
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$9.00
5/16/2025
Omeros Corporation stock logo
OMER
Omeros
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
5/13/2025
Omeros Corporation stock logo
OMER
Omeros
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$36.00 ➝ $36.00
5/7/2025
Omeros Corporation stock logo
OMER
Omeros
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$36.00 ➝ $36.00
4/11/2025
Omeros Corporation stock logo
OMER
Omeros
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$36.00 ➝ $36.00
(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
N/AN/AN/AN/A$4.28 per shareN/A
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
$39.18M6.44N/AN/A($1.51) per share-3.55
Neos Therapeutics, Inc. stock logo
NEOS
Neos Therapeutics
$64.65M0.89N/AN/A($0.12) per share-9.58
Omeros Corporation stock logo
OMER
Omeros
N/AN/AN/AN/A($3.15) per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
-$49.59M-$0.99N/AN/AN/AN/A-22.85%-22.02%8/4/2025 (Estimated)
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
-$73.73MN/A0.00N/AN/AN/AN/AN/A9/16/2025 (Estimated)
Neos Therapeutics, Inc. stock logo
NEOS
Neos Therapeutics
-$16.90M-$0.34N/AN/AN/A-38.35%N/A-28.46%N/A
Omeros Corporation stock logo
OMER
Omeros
-$156.82M-$2.65N/AN/AN/AN/AN/A-59.68%8/6/2025 (Estimated)

Latest NEOS, DSGN, OMER, and NBTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q2 2025
Omeros Corporation stock logo
OMER
Omeros
-$0.46N/AN/AN/AN/AN/A
8/4/2025Q1 2025
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
-$0.32N/AN/AN/AN/AN/A
5/15/2025Q1 2025
Omeros Corporation stock logo
OMER
Omeros
-$0.60-$0.65-$0.05-$0.58$0.40 millionN/A
5/14/2025Q1 2025
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
-$0.28-$0.31-$0.03-$0.31N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
N/AN/AN/AN/AN/A
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
N/AN/AN/AN/AN/A
Neos Therapeutics, Inc. stock logo
NEOS
Neos Therapeutics
N/AN/AN/AN/AN/A
Omeros Corporation stock logo
OMER
Omeros
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
N/A
28.37
28.37
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
N/A
1.04
1.04
Neos Therapeutics, Inc. stock logo
NEOS
Neos Therapeutics
N/A
0.66
0.53
Omeros Corporation stock logo
OMER
Omeros
N/A
1.16
1.16

Institutional Ownership

CompanyInstitutional Ownership
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
56.64%
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
38.81%
Neos Therapeutics, Inc. stock logo
NEOS
Neos Therapeutics
33.13%
Omeros Corporation stock logo
OMER
Omeros
48.79%

Insider Ownership

CompanyInsider Ownership
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
31.20%
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
3.45%
Neos Therapeutics, Inc. stock logo
NEOS
Neos Therapeutics
3.80%
Omeros Corporation stock logo
OMER
Omeros
12.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
4056.77 million39.06 millionOptionable
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
10047.13 million45.51 millionNot Optionable
Neos Therapeutics, Inc. stock logo
NEOS
Neos Therapeutics
21349.76 millionN/AOptionable
Omeros Corporation stock logo
OMER
Omeros
21058.59 million51.04 millionOptionable

Recent News About These Companies

Julian Lucas on Hilton Als’s “The Islander”
Q1 2025 Omeros Corp Earnings Call

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Design Therapeutics stock logo

Design Therapeutics NASDAQ:DSGN

$4.04 -0.13 (-3.12%)
Closing price 07/10/2025 04:00 PM Eastern
Extended Trading
$4.06 +0.01 (+0.37%)
As of 07/10/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

Nanobiotix stock logo

Nanobiotix NASDAQ:NBTX

$5.36 +0.02 (+0.28%)
Closing price 07/10/2025 03:58 PM Eastern
Extended Trading
$5.36 0.00 (0.00%)
As of 07/10/2025 04:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.

Neos Therapeutics stock logo

Neos Therapeutics NASDAQ:NEOS

Neos Therapeutics, Inc., a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its products are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms. The company manufactures and markets Adzenys XR-ODT amphetamine for the treatment of ADHD; Cotempla XR-ODT methylphenidate to treat ADHD; Adzenys ER amphetamine for the treatment of ADHD; and generic Tussionex, a hydrocodone and chlorpheniramine polistirex XR oral suspension for cough and upper respiratory symptoms of a cold. It also offers NT0502, a clinical-stage product candidate that has completed Phase I pilot pharmacokinetic trial for the treatment of neurological conditions associated with excessive salivation and drooling to reduce chronic sialorrhea in patients. The company was incorporated in 2009 and is headquartered in Grand Prairie, Texas.

Omeros stock logo

Omeros NASDAQ:OMER

$3.46 +0.08 (+2.37%)
Closing price 07/10/2025 04:00 PM Eastern
Extended Trading
$3.45 -0.01 (-0.32%)
As of 07/10/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.